On Friday, Shares of Hanesbrands Inc. (NYSE:HBI), lost -0.31% to $32.35.
Hanesbrands, declared that it has awarded Wake Forest Baptist Medical Center and its medical professionals with the company’s first Hanes for Good Champion Award for outstanding commitment to community service.
Hanes has partnered with the medical center since 2012 to conduct eight volunteer surgical missions to the Dominican Republic where Hanes has more than 8,000 employees. The medical center’s otolaryngology medical teams have performed more than 500 life-altering ear, nose and throat surgeries and have treated more than 4,000 patients.
Hanesbrands Inc., a consumer goods company, designs, manufactures, sources, and sells a range of basic apparels for men, women, and children in the United States. The company operates through four segments: Innerwear, Activewear, Direct to Consumer, and International.
Shares of Continental Resources, Inc. (NYSE:CLR), declined -0.74% to $ 46.63, during its last trading session.
Continental Resources, declared first quarter 2015 operating and financial results.
Continental stated a net loss of $132.0 million, or $0.36 per diluted share, for the first quarter of 2015. Adjusted net loss for the first quarter of 2015 was $33.8 million, or $0.09 per diluted share.
EBITDAX for the first quarter of 2015 was $439.4 million, contrast with EBITDAX of $775.4 million for the first quarter of 2014, reflecting the decline in average commodity prices since June 2014.
Continental Resources, Inc. explores, develops, and produces crude oil and natural gas properties in the north, south, and east regions of the United States. The company sells its crude oil production to end users, in addition to midstream marketing companies or crude oil refining companies at the lease.
At the end of Friday’s trade, Shares of Pharmacyclics, Inc. (NASDAQ:PCYC), gained 0.65% to $ 261.25.
Pharmacyclics, declared that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending a change to the terms of the marketing authorization for IMBRUVICA® (ibrutinib) in the European Union to indicate the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one preceding therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.1 WM is a rare, slow growing form of blood cancer.2 IMBRUVICA is also the first and only FDA-approved treatment for WM in the United States.3 The CHMP recommendation follows the January 2015 U.S. Food and Drug Administration (FDA) full approval of IMBRUVICA to treat all lines of patients with WM.
IMBRUVICA is jointly developed and commercialized in the United States by Pharmacyclics and Janssen Biotech, Inc. In Europe, Janssen-Cilag International NV (Janssen) holds the marketing authorization and its associates market IMBRUVICA in EMEA (Europe, Middle East, Africa), in addition to the rest of the world. IMBRUVICA is already approved in Europe to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL) and adult patients with chronic lymphocytic leukemia (CLL) who have received at least one preceding therapy or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
Pharmacyclics, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for the treatment of cancer and immune-mediated diseases in the United States.
Finally, Pall Corporation (NYSE:PLL), ended its last trade with 0.24% gain, and closed at $ 124.59.
Pall Corporation (PLL) stated financial results for the third quarter of fiscal year 2015 which ended April 30, 2015.
- Sales in the quarter were flat; up 11% in local currency
- Diluted EPS in the quarter of $0.89 up 11%; pro forma diluted EPS of $0.92, up 14%
- Free cash flow in the nine months of $321 million, up 10%
Third Quarter and Nine Months Sales and Earnings Overview
Third Quarter and Nine Months Sales and Earnings Overview
Third quarter sales were $681.1 million contrast to $682.4 million last year. Sales in local currency were up 11%, and about 9% not taking into account acquisitions. Diluted EPS were $0.89 in the quarter, contrast to $0.80 last year. Pro forma diluted EPS (1) were $0.92, a 14% enhance contrast to $0.81 a year earlier, counting a headwind of about $0.15 from foreign currency translation. Not taking into account the impact of foreign currency translation, pro forma diluted EPS raised by 32%.
Pall Corporation manufactures and markets filtration, separation, and purification products; and integrated systems solutions worldwide. Its Life Sciences segment provides technologies that facilitate the process of drug discovery, development, regulatory validation, and production, which are used in the research laboratories, pharmaceutical, biotechnology, and food and beverage industries, in addition to in hospitals.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
